SLIT3 promotes myogenic differentiation as a novel therapeutic factor against muscle loss.

ABSTRACT:

Background

Sarcopenia and osteoporosis frequently co-occur in the elderly and have common pathophysiological determinants. Slit guidance ligand 3 (SLIT3) has been recently discovered as a novel therapeutic factor against osteoporosis, and a SLIT3 fragment containing the second leucine-rich repeat domain (LRRD2) had a therapeutic efficacy against osteoporosis. However, a role of SLIT3 in the skeletal muscle is unknown.

Methods

Skeletal muscle mass, strength, and/or physical activity were evaluated in Slit3^-/- , ovariectomized, and aged mice, based on the measurements of muscle weight and grip strength, Kondziella's inverted hanging test, and/or wheel-running test. Skeletal muscles were also histologically evaluated by haematoxylin and eosin staining and/or immunofl

SUBMITTER: Cho HJ 

PROVIDER: S-EPMC8718016 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature